Drug Rett Syndrome

Daybue

Payments companies reported to CMS as associated with Daybue. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.

$1.3Massociated payments (2023-2025)
4,655clinicians with associated payments
1company reporting

By year

2023 $204K
2024 $386K
2025 $670K

Payments reported as associated with Daybue, per program year, as reported to CMS.

Who makes it

Specialties most often involved

Neurology With Special Qualifications In Child Neurology $474K
Developmental - Behavioral Pediatrics $164K
Pediatrics $145K
Internal Medicine $96K
Pediatrics (Nurse Practitioner) $78K
Epilepsy $61K

Where the associated payments went, by the receiving clinician's specialty.

Clinicians most associated with Daybue

These are the largest totals companies reported as associated with Daybue. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.

ClinicianLocationSpecialtyAssociated payments (2023-2025)
Caroline Buchanan Greenville, SC Developmental - Behavioral Pediatrics $162,457.72
Arthur Beisang Saint Paul, MN Pediatrics $107,595.63
Haya Mayman Medfield, MA Internal Medicine $89,595.00
Katherine Labiner Austin, TX Epilepsy $53,830.02
Gian Rossi Lakeland, FL Neurology With Special Qualifications In Child Neurology $50,091.97
Timothy Feyma Bloomington, MN Neurology With Special Qualifications In Child Neurology $49,309.97
Jesus Pina Garza Nashville, TN Neurology With Special Qualifications In Child Neurology $48,969.04
Rajsekar Rajaraman Los Angeles, CA Neurology With Special Qualifications In Child Neurology $43,326.07
Alan Percy Birmingham, AL Neurology With Special Qualifications In Child Neurology $40,316.33
Shannon Standridge Cincinnati, OH Neurology With Special Qualifications In Child Neurology $32,767.29

Prescribed Daybue?

See what its makers reported for your doctor. Two steps, private, no account.

Check my doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.